NFE2L2 and neuroblastoma: Of note, our own studies using Drosophila and neuroblastoma cells suggest that lithium and GSK-3 inhibitors (TDZD8) are weak activators of Nrf2, relative to Keap1-Nrf2 disruption, in response to amyloid toxicity (Kerr et al., 2017).